GRL 0617

Biological Activity

GRL 0617 is a coronavirus papain-like protease (Plpro) inhibitor (IC₅₀ values are 0.6 and 0.8 μM for SARS-COV and SARS-CoV-2 PLpro, respectively). Inhibits deubiquitination activity of SARS-CoV PLpro. Displays no inhibition of human deubiquitinating enzymes. Improves cell viability following SARS-CoV infection. Inhibits SARS-CoV-2 viral replication and induces antiviral immune signaling pathways following SARS-CoV-2 infection in CaCo-2 cells.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
   Ratia et al.
   Proc.Natl.Acad.Sci.USA., 2008;105:16119
2. Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-Like protease.
   Freitas et al.
   ACS Infect.Dis., 2020;
3. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.
   Shin et al.
   Nature., 2020;

Product Datasheets